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  EVIDENCE-BASED ANSWER 
Although lowering diastolic blood pressure (DBP) is associated with reduced cardiovascular events, systolic 
blood pressure (SBP) is a more robust predictor of cardiovascular risk than DBP and should now be used to 
diagnose, stage, and treat hypertension. 
Lowering diastolic blood pressure (DBP) to <90 mm Hg in hypertensive individuals of all ages decreases the 
risk of cardiovascular events including myocardial infarction (MI), heart failure, and sudden death (strength of 
recommendation [SOR]: A, based on systematic review of randomized controlled trials). However, there is no 
consensus regarding how far to lower DBP. A “J-shaped” increase in cardiovascular risks with DBP <85 mm 
Hg may apply under certain conditions. 
  EVIDENCE SUMMARY 
The concept of a continuous graded relationship between DBP and cardiovascular risk is supported by a meta-
analysis of 14 randomized clinical trials showing that lowering DBP by 6 mm Hg reduced the risk of coronary 
heart disease by 14% (95% confidence interval [CI], 4%–22%; P<.01; NNT=200).1 Throughout the range of 
DBP in study subjects, 70–115 mm Hg, a lower DBP was associated with a lower risk of coronary heart 
disease. 
However, there is concern that lowering DBP too much may actually increase cardiovascular risk. A 10-year 
observational study showed that in patients with a history of ischemic heart disease, the incidence of fatal MI 
was lowest when DBP was between 85 to 90 mm Hg and increased with DBP <85 mm Hg, thus demonstrating 
a J-shaped curve.2 
Farnett et al3 derived a summary curve from 13 studies that stratified cardiovascular outcomes by level of 
achieved blood pressure; the nadir of the curve for ischemic heart disease events occurred at 86 to 89 mm Hg 
DBP. The risk was independent of type of drug therapy, and more pronounced in study subjects with known 
cardiovascular disease. 
A meta-analysis of 7 randomized controlled trials involving 40,233 hypertensive patients used statistical 
modeling to determine the shape of the “mortality curve” over a range of DBP categories, defined in 10-mm Hg 
increments from 65 to 106. The subjects received mainly beta-blockers or thiazide diuretics; controls received 
placebo or no treatment.4 Both groups demonstrated increased risk for cardiovascular and all-cause death at 
the lowest DBP levels. Among treated patients, overall death rate was lowest with a DBP in the range of 76 to 
85 mm Hg; among controls the nadir was 86 to 95 mm Hg. 
The Hypertension Optimal Treatment (HOT) trial5 was specifically designed to determine the optimal target 
blood pressure for hypertensive patients: 18,790 men and women with DBP 100 to 115 mm Hg were randomly 
assigned to target DBP groups of <90, <85, or <80 mm Hg. All were treated with felodipine and other agents in 
a stepped-care protocol; average follow-up was 3.8 years. The lowest incidence of cardiovascular events 
occurred at a mean DBP of 82.6 mm Hg and fewest cardiovascular deaths at 86.5 mm Hg. Further reductions 
in DBP neither lowered nor increased cardiovascular risk. 
A French cohort study6 followed over 4700 hyper-tensive men for an average of 14 years. These men had their 
hypertension treated in usual fashion by their own physicians. In this group, SBP was much more accurate 
than DBP in classifying severity of hypertension and in predicting cardiovascular risk. 
  RECOMMENDATIONS FROM OTHERS 
The Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure 
(JNC VII)7 and the World Health Organization–International Society of Hyper-tension Guidelines8 state that the 
relationship between cardiovascular risk and blood pressure is continuous, without a lower threshold. Target 
blood pressure goals are <140/90 mm Hg in uncomplicated hypertension and <130/80 mm Hg for individuals 
with diabetes or kidney disease. The National High Blood Pressure Education Program stressed that SBP, not 
DBP, should become the major criterion for diagnosis and treatment of hypertension.9 
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In light of JNC VII, there may be some confusion on the part of patients as to “normal” 
blood pressure and indications for treatment. In fact, on the first page of the NHLBI web 
site, “Your Guide to Lowering Blood Pressure,” the statement is made that “normal blood 
pressure is less than 120 mm Hg systolic and less than 80 mm Hg diastolic.” They later go 
on to describe the category of prehypertension. It is important to understand the concept 
and implications of prehypertension, and the “J-shaped” curve in counseling our patients 
on achieving optimal blood pressure control. 
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